In this episode, trauma surgeon and EndoShunt's co-founder Milad Behbahaninia and CEO Tyler Zanon share how the company was born from frontline frustration: critically injured patients bleeding out before surgeons can reach hard-to-access injuries. They explain why endovascular innovation is the next horizon in trauma care, how the team engineered a solution that fits existing clinical workflows, and why incremental, surgeon-built improvements can drive outsized impact. They walks through EndoShunt’s rapid maturation since 2023, including multiple preclinical models, meaningful non-dilutive funding, a shrinking catheter profile toward a 7 French design, and plans toward an FDA submission next year.
Podden och tillhörande omslagsbild på den här sidan tillhör
Project Medtech. Innehållet i podden är skapat av Project Medtech och inte av,
eller tillsammans med, Poddtoppen.
